NAMS vs NKTR Stock Comparison
NAMS currently leads NKTR in this stock comparison, with AIQ scores of 41 vs 39. The clearest difference is quality, while NKTR has the stronger value profile.
What is the main difference between NAMS and NKTR?
NAMS leads the current stock comparison as NewAmsterdam Pharma Company N.V., with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
NewAmsterdam Pharma Company N.V. vs Nektar Therapeutics
NAMS leads
NAMS leads by 2 AIQ points, primarily on Quality and Risk Resilience, having only recently taken the lead back from NKTR.
Fragile: 4 of 6 evidence groups support NAMS, the lead recently changed hands, and its current signal state is conflicted.
NewAmsterdam Pharma Company N.V.
Nektar Therapeutics
The Algovestiq AIQ Score currently favors NAMS over NKTR, 41 versus 39 as of Nov 15, 2026. NAMS's advantage is driven primarily by stronger quality and risk resilience, while NKTR holds the stronger value profile. NAMS also shows the stronger technical structure relative to its 50-day moving average. 4 of 6 covered evidence groups favor NAMS today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 2 points. NAMS lead: Reversed — NKTR led by 6 AIQ points 30 sessions ago; NAMS now leads by 2.
Compare NewAmsterdam Pharma Company N.V. and Nektar Therapeutics across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare NAMS and NKTR against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality58 vs 49NAMS +9
- Risk Resilience48 vs 41NAMS +7
- Value42 vs 47NKTR +5
- Momentum22 vs 25Even
4 of 6 evidence groups favor NAMS. NAMS’s edge is concentrated in quality and risk resilience; NKTR keeps a meaningful value edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Value +2, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 6 active signals are unchanged.
Largest factor move: Quality -9
No signal started or stopped since the prior session; its 3 active signals are unchanged.
NAMS's lead widened by 2 AIQ points in the latest session.
Deeper signal detail for each name lives on its own signals page — NAMS and NKTR both carry a full feed there.
The central trade-off
NAMS (NewAmsterdam Pharma Company N.V.): the stronger current systematic profile, led by quality and risk resilience.
NKTR (Nektar Therapeutics): the counter-case, on value, valuation.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
NAMSNAMS on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
NAMSNAMS on combined revenue and EPS growth.
Value
NKTRNKTR on the peer-relative Value factor, by 5 points.
Momentum
EvenThe two are level on Momentum.
Lower downside
NAMSNAMS on Risk Resilience, by 7 points.
Analyst upside
NAMSNAMS on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | NAMS | NKTR | Note |
|---|---|---|---|
| Implied upside to target | +202.9% | +156.9% | NAMS has more room |
| Target dispersion | 0% | +104.4% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 16 | 15 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 6 covered evidence groups favor NAMS. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 41 vs 39 |
| Fundamentals | NAMSon balance | revenue growth 4.2% vs -7.4%; EPS growth 73.1% vs -32.5%; TTM ROE -2.8% vs -6.5%; gross margin 97.8% vs -29%; operating margin -9% vs -3% — NAMS takes 4 of 5 decided legs, not all of them |
| Valuation | NKTR | Value 42 vs 47 |
| Technicals | NAMS | Price vs 50-day -6.4% vs -23.1%; vs 200-day -30.9% vs -42.7% |
| Risk Resilience | NAMS | Risk Resilience 48 vs 41 |
| Analyst expectations | NAMS | Target upside 202.9% vs 156.9% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of NAMS and NKTR and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 2 points. (argues the conclusion is provisional)
- The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on NAMS.
How the comparison changed
120 daily snapshots · May 27 – Nov 13NAMS lead: Reversed — NKTR led by 6 AIQ points 30 sessions ago; NAMS now leads by 2.
- Today
- NAMS +2
- 41 vs 39
- 7 sessions ago
- NKTR +2
- 39 vs 41
- 30 sessions ago
- NKTR +6
- 34 vs 40
- 90 sessions ago
- NKTR +13
- 40 vs 53
The lead changed hands once in this window, most recently on Jun 2 when NAMS moved ahead of NKTR.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
1 bullish / 3 bearish / 2 neutral, conflicted
Only NAMS
- ADX Trend Weakening — neutral, trend, medium horizon
- Beta Spike Warning — bearish, risk_regime, long horizon
- MACD Histogram Expanding Bullish — bullish, momentum, short horizon
0 bullish / 2 bearish / 1 neutral
No signal that the other name lacks.
Both carry 3 more signals that do not separate them: Death Cross Active, ATR Expansion - Breakout Mode, Downtrend Structure Active.
NAMS leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.85%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.05%, AIQ -2 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1NKTR closes the Quality gap — currently 9 points behind, the largest single contributor to NAMS's edge.
- 2NKTR's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3NAMS's conflicting signal state resolves bearish — it currently carries 1 bullish and 3 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
NAMS leads on balance| Metric | NAMS | NKTR |
|---|---|---|
| Revenue growth (YoY) | 4.2% | -7.4% |
| EPS growth (YoY) | 73.1% | -32.5% |
| Gross margin | 97.8% | -29% |
| Operating margin | -9% | -3% |
| Return on equity (TTM) | -2.8% | -6.5% |
| Debt to equity | 0 | 0.09 |
Performance
Split across windows| Metric | NAMS | NKTR |
|---|---|---|
| 1 week (5 sessions) | 6.6% | 0% |
| 1 month (20 sessions) | 1.6% | 4.2% |
| 3 months (63 sessions) | -25.1% | -48.7% |
| 6 months (126 sessions) | -43.2% | -47.2% |
| Year to date | -42.6% | -11.8% |
| 1 year (252 sessions) | -47.4% | -35.4% |
Technicals
NAMS has the stronger structure| Metric | NAMS | NKTR |
|---|---|---|
| RSI (14) | 47.3 | 37.9 |
| ADX (14) | 16.7 | 32.8 |
| Price vs 50-day | -6.4% | -23.1% |
| Price vs 200-day | -30.9% | -42.7% |
| Volatility (1M, annualized) | 69.8% | 48.4% |
Risk
NAMS is the more resilient| Metric | NAMS | NKTR |
|---|---|---|
| Beta | 1.43 | 1 |
| Sharpe ratio | -0.91 | -0.11 |
| Sortino ratio | -1.25 | -0.18 |
| Max drawdown | -54.4% | -64.3% |
| Current drawdown | -51.4% | -62.9% |
| Annualized volatility | 53.8% | 84% |
| Value at risk (95%) | -5.2% | -6.5% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, NAMS or NKTR?
On the Algovestiq AIQ Score, NAMS is the stronger of the two as of Nov 15, 2026, scoring 41 against NKTR's 39. The edge comes from quality and risk resilience. NKTR is not without a case — it holds the better value profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is NAMS or NKTR the better buy right now?
NAMS carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 4 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 2 points. Treat the lead as provisional.
Why does the AIQ Score favor NAMS over NKTR?
The composite weights Quality, Value, Momentum and Risk Resilience. NAMS leads Quality by 9 points; NAMS leads Risk Resilience by 7 points; NKTR leads Value by 5 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, NAMS or NKTR?
Analyst price targets imply +202.9% upside for NAMS and +156.9% for NKTR, so the Street currently favors NAMS. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, NAMS or NKTR?
NKTR is the better-valued of the two on the peer-relative Value factor. NKTR on the peer-relative Value factor, by 5 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, NAMS or NKTR?
NAMS on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, NAMS or NKTR?
The two are level on Momentum. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, NAMS or NKTR?
NAMS is the more resilient of the two, so the other name carries the higher downside risk. NAMS on Risk Resilience, by 7 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is NAMS more profitable than NKTR?
The profitability evidence is mixed: gross margin 97.8% vs -29%; operating margin -9% vs -3%; ttm roe -2.8% vs -6.5%. NAMS leads on two measures and NKTR on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is NAMS's lead over NKTR getting stronger or weaker?
NAMS lead: Reversed — NKTR led by 6 AIQ points 30 sessions ago; NAMS now leads by 2. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands once in that window, most recently on 2026-06-02, when NAMS moved ahead of NKTR.
What would change the NAMS vs NKTR verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: NKTR closes the Quality gap — currently 9 points behind, the largest single contributor to NAMS's edge; NKTR's Death Cross Active resolves — a bearish trend rule currently active against it; NAMS's conflicting signal state resolves bearish — it currently carries 1 bullish and 3 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about NAMS and NKTR?
NAMS: 1 bullish / 3 bearish / 2 neutral, conflicted. NKTR: 0 bullish / 2 bearish / 1 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on NAMS is Death Cross Active (bearish, long horizon). On NKTR it is Death Cross Active (bearish, long horizon).
Compare NAMS and NKTR with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.